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Abstract 
Background: Interleukin‑7 (IL‑7) is a critical factor for T cell development and for maintaining and restoring homeo‑
stasis of mature T cells. Polymorphisms at α‑chain of the IL‑7 receptor (IL7R or CD127) gene are related to evolution of 
HIV‑infection, but there are no data concerning the evolution of hepatitis C virus (HCV) infection. The aim of this study 
was to analyze the association between IL7R polymorphisms and severe liver disease in HCV/HIV coinfected patients.
Methods: We performed a cross‑sectional study in 220 naïve patients who underwent a liver biopsy. IL7R polymor‑
phisms (rs6897932, rs987106 and rs3194051) were genotyped using the GoldenGate® assay. The outcome variables 
were: (a) liver biopsy: advanced fibrosis (F ≥ 3), severe activity grade (A3); (b) non‑invasive indexes: advanced fibrosis 
(APRI ≥1.5 and FIB‑4 ≥3.25). Logistic regression analysis was used to investigate the association between IL7R poly‑
morphisms and outcome variables. This test gives the differences between groups and the odds ratio (OR) for liver 
disease.
Results: Patients with rs6897932 CC genotype had higher likelihood of having A3 than patients with rs6897932 
CT/TT (adjusted odds ratio (aOR) = 4.16; p = 0.026). Patients with rs987106 TT genotype had higher odds of having 
F ≥ 3 (aOR = 3.09; p = 0.009) than rs987106 AA/AT carriers. Finally, patients with rs3194051 AA genotype had higher 
odds of having severe liver fibrosis (F ≥ 3; APRI ≥1.5, and FIB4 ≥3.25) than patients with rs3194051 AG/GG genotype 
[aOR = 2.73 (p = 0.010); aOR = 2.52 (p = 0.029); and aOR = 4.01 (p = 0.027); respectively]. The CTA haplotype (com‑
prised of rs6897932, rs987106, and rs3194051) carriers had higher odds of having F ≥ 3 (aOR = 1.85; p = 0.012), APRI 
≥1.5 (aOR = 1.94; p = 0.023), and FIB4 ≥3.25 (aOR = 2.47; p = 0.024). Conversely, the CAG haplotype carriers had 
lower odds of having F ≥ 3 (aOR = 0.48; p = 0.011), APRI ≥1.5 (aOR = 0.48; p = 0.029), and FIB4 ≥3.25 (aOR = 0.29; 
p = 0.010).
Conclusions: The presence of IL7R polymorphisms seems to be related to severe liver disease in HIV/HCV coinfected 
patients, because patients with unfavorable IL7R genotypes (rs6897932 CC, rs987106 TT, and rs3194051AA) had a 
worse prognosis of CHC.
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Background
Interleukin-7 (IL-7) is required for T cell development 
and for maintaining and restoring homeostasis of mature 
T cells. IL-7 is a critical factor in maintaining or inducing 
an effective antiviral CD4+ and CD8+ T cell responses 
[1]. IL-7 is implicated in the proliferation and survival 
of early T and B cells in the thymus and bone marrow, 
respectively. Besides, in the periphery, IL-7 enhances 
survival and proliferation of naïve and memory T cells, 
regulating the T cell homeostasis [2]. The responsiveness 
of IL-7 is dependent on expression of the IL-7 receptor, 
which is composed of the high-affinity α-chain (IL7Rα 
or CD127) and the common cytokine receptor gamma 
chain (CD132) [3].
In human immunodeficiency virus (HIV) infection, 
the interaction between IL-7 and CD127 has impact 
on development, survival, and proliferation of CD4+ 
T cells [4]. During HIV infection, IL-7 regulatory path-
way is activated and IL-7 levels are increased, but it is 
not enough to maintain T cell homeostasis due to pro-
gressive destruction of CD4+ T cell [5]. In hepatitis C 
virus (HCV) infection, hepatocytes stimulated by type I 
interferon (IFN) are able to produce IL-7 and eventually 
lead to viral clearance and disease resolution in the liver 
[6]; and the early expression of CD127 on HCV-specific 
T cells predicts the HCV clearance during acute HCV 
infection [7]. However, IL-7 and CD127 levels are signifi-
cantly diminished during chronic HCV infection, leading 
to an impaired HCV-specific cytotoxic T cell reactivity 
[8, 9].
The IL7Rα (CD127) is encoded by IL7R gene, which 
plays an essential role in several human diseases. Thus, 
IL7R polymorphisms have been studied in several infec-
tious diseases [10, 11] and autoimmune diseases [12], 
showing a key role in the evolution of patients. In HIV 
infection, IL7R polymorphisms have been associated 
with the decline in the CD4+ cell count in untreated 
HIV-infected subjects [13], and CD4+ T-cell recovery 
in HIV-infected patients on combination antiretroviral 
therapy (cART) [14]. In HCV infection, we have recently 
reported an association between IL7R polymorphisms 
and virological response to HCV therapy with pegylated 
interferon alpha plus ribavirin (pegIFNα/ribavirin) [15]. 
Thus, IL7R polymorphisms seem to play a crucial role in 
the physiopathology of these diseases.
The cART has made of HIV infection a chronic man-
ageable disease in high income countries [16]. In this 
setting, chronic hepatitis C (CHC) has turned into an 
important comorbidity and a major cause of death in 
HIV/HCV coinfected patients [17–19], since HIV infec-
tion accelerates the natural history of CHC and increases 
liver-related morbidity and mortality [20–22]. Interest-
ingly, uncontrolled HIV replication and low CD4 counts 
are both associated with accelerated liver fibrosis pro-
gression in HIV/HCV coinfected patients [23], sug-
gesting that earlier use of antiretroviral therapy could 
ameliorate this harmful effect [24].
The aim of this study was to analyze the association 
between IL7R polymorphisms (rs6897932, rs987106, and 




We carried out a cross-sectional study in HIV/HCV coin-
fected patients that underwent a liver biopsy at Hospital 
Gregorio Marañón (Madrid, Spain) between September 
2000 and November 2008. All patients were of European 
ancestry.
Liver biopsies were performed on patients who were 
potential candidates for anti-HCV therapy and had not 
received previous interferon therapy (naïve for HCV-
treatment). Selection criteria were: no clinical evidence 
of hepatic decompensation, detectable HCV RNA by 
polymerase chain reaction (PCR), negative hepatitis B 
surface antigen, availability of DNA sample, CD4+ lym-
phocyte count higher than 200 cells/µL, and stable cART 
for at least 6  months before study entry or no need for 
cART according to treatment guidelines used in the 
study period [25, 26]. Patients with active opportunistic 
infections, active drug addiction, and other concomitant 
severe diseases were excluded. Thus, from our cohort of 
361 HIV/HCV coinfected patients with liver biopsy data, 
only 220 patients had data available of IL7R genotypes.
The study was conducted in accordance with the Dec-
laration of Helsinki and patients gave their written con-
sent for the study. The Institutional Review Board and the 
Research Ethic Committee of the Instituto de Salud Car-
los III approved the study.
Epidemiological and clinical data
Clinical and epidemiological data were obtained from 
medical records. Consumption of more than 50 g of alco-
hol per day for at least 12  months was considered as a 
high intake. Body mass index (BMI) was calculated as the 
weight in kilograms divided by the square of the height in 
meters. The duration of HCV infection for patients with 
a history of intravenous drug use (IDU; 87.7% of patients) 
was estimated starting from the first year they shared 
needles and other injection paraphernalia, which are the 
most relevant risk practices for HCV transmission [27]. 
The duration of HCV infection was not calculated when 
the date of initiation of their HCV infection could not be 
determined with certainty (n = 19).
Biochemistry panel was measured using an autoana-
lyzer Hitachi 912 (Boehringer Mannheim, Germany), 
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while patients were fasting. The degree of insulin resist-
ance was estimated for each patient using the homeo-
static model assessment (HOMA) [28]: fasting plasma 
glucose (mmol/L) times fasting serum insulin (mU/L) 
divided by 22.5 [28]. Non-invasive liver fibrosis indexes 
were calculated according to the formula originally 
described for the aspartate aminotransferase to plate-
let ratio index (APRI): aspartate aminotransferase 
(AST) [U/L]/upper limit of normal for AST (ULN)/
(platelet [109/L])  ×  100 [29] and the FIB-4 index: age 
[years] ×  AST [U/L]/(platelets [109/L]) ×  (alanine ami-
notransferase (ALT) [U/L])1/2) [30]. Although these 
indexes may have a poor ability to identify patients with 
intermediate stage of fibrosis [31], we have previously 
reported that the diagnostic performance of APRI and 
FIB-4 indexes were acceptable for diagnosis of advanced 
fibrosis in HIV/HCV-coinfected patients [32].
HCV assays
HCV infection was documented in all patients by 
enzyme-linked immunosorbent assay and PCR test. HCV 
genotype was determined by hybridization of biotin-
labeled PCR products to oligonucleotide probes bound 
to nitrocellulose membrane strips (INNO-LiPA HCV 
II, Innogenetics, Ghent, Belgium). Plasma HCV-RNA 
viral load was measured by PCR (Cobas Amplicor HCV 
Monitor Test, Branchburg, NJ, USA) and real-time PCR 
(COBAS AmpliPrep/COBAS TaqMan HCV test); and 
results were reported in terms of international units 
per milliliter (IU/mL), with a lower limit of detection of 
10 IU/mL.
Liver biopsy
Liver biopsies were performed as we described previously 
[32]. The samples were always evaluated by the same 
pathologist, who was unaware of the patients’ clinical or 
laboratory data. Liver fibrosis and necroinflammatory 
activity were estimated according to Metavir score as fol-
lows [33]: F0, no fibrosis; F1, mild fibrosis; F2, significant 
fibrosis; F3, advanced fibrosis; and F4, definite cirrhosis. 
The degree of necroinflammation (activity grade) was 
scored as follows: A0, no activity; A1, mild activity; A2, 
moderate activity; A3, severe activity.
Genotyping of IL7R polymorphisms
We have analyzed the most common single nucleotide 
polymorphisms (SNPs) including at IL7R gene, using 
the databases of HapMap Project (http://snp.cshl.org/
cgi-perl/gbrowse/hapmap_B35/) and NCBI (dbSNP) 
(http://www.ncbi.nlm.nih.gov/entrez/). The selection 
criteria were: (1) SNPs located at a putative regula-
tory region, although their effect has not been tested or 
demonstrated. (2) Allelic frequency greater than 20% in 
European people, because it is easier to detect a modest 
individual effect with a high SNP frequency >20% in the 
population when small sample sizes are used [34]. (3) A 
tag-SNP was selected when more than 1 SNP per gene 
was found and they had high linkage disequilibrium (LD). 
In summary, three SNPs [rs987106 (intronic region), 
rs6897932 (exon 6) and rs3194051 (exon 8)] were used 
for the genetic association study.
Genomic DNA was extracted from peripheral blood 
with Qiagen kit (QIAamp DNA Blood Midi/Maxi; Qia-
gen, Hilden, Germany). DNA samples were genotyped at 
the Spanish National Genotyping Center (CeGen; http://
www.cegen.org/) using GoldenGate® assay with Vera-
Code® Technology (Illumina Inc. San Diego, CA, USA) 
[35].
Outcome variables
We analyzed several outcome variables related to sever-
ity of liver disease [31]: (a) liver biopsy: advanced fibro-
sis (F  ≥  3), severe activity grade (A3); (b) non-invasive 
indexes: advanced fibrosis (APRI ≥1.5 and FIB-4 ≥3.25). 
These CHC-related outcomes were developed after a 
minimum follow-up time of 10 years with HCV infection.
Statistical analysis
For the description of the study population, p values were 
estimated with Chi square test for categorical variables.
The genetic analysis was carried out according to 
additive, recessive and dominant models, selecting the 
model that best fitted the outcome variable analyzed in 
each case. The genetic association study was performed 
via logistic regression analysis. This test gives the differ-
ences between groups and the odds ratio (OR) for liver 
disease. Each regression analysis was always adjusted by 
the most significant co-variables associated with each 
one of the outcome variables, avoiding the over-fitting of 
the regression. The co-variables were selected by “Step-
wise” algorithm (at each step, factors were considered for 
removal or entry: a p value for entry and exit of 0.15 and 
0.20, respectively), including gender, age, alcohol intake, 
BMI, HOMA, nadir CD4+ T-cells, AIDS, undetect-
able HIV-RNA (<50 copies/ml), CD4+ T-cells, time of 
HCV infection, time on cART, type of cART, HCV-RNA 
≥500,000 IU/ml, and HCV genotype. The percentage of 
patients that were excluded in each of the multivariable 
analyses due to incomplete data of covariates was always 
<5%.
These analyses were performed by using the IBM 
SPSS Statistics for Windows, Version 21.0 (IBM Corp, 
Chicago, Armonk, NY, USA). In addition, pair-wise LD 
and Hardy–Weinberg equilibrium (HWE) analyses were 
computed by Haploview 4.2 software. Haplotype-based 
association testing was performed using Plink software 
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(http://pngu.mgh.harvard.edu/~purcell/plink/) and each 
haplotype was compared with the rest of haplotypes 
(there was no reference category). All p values were two-
tailed and statistical significance was defined as p < 0.05.
Results
Characteristics of the patients
Table 1 shows the epidemiological and clinical character-
istics of 220 HIV/HCV coinfected patients.
Characteristics of IL7R polymorphisms
A strong LD (non-random association of alleles at dif-
ferent loci) among IL7R polymorphisms was found 
(D′ ≥ 0.999), meaning that there is no evidence for recom-
bination between these SNPs. However, the r-square 
among SNPs was low (r-square <0.50), meaning that the 
IL7R polymorphisms did not provide exactly the same 
information and the IL7R polymorphisms cannot substi-
tute one for another (Figure 1a). Additionally, all SNPs had 
a minimum allele frequency (MAF) >5%, displayed miss-
ing values <5%, and were in HWE (p > 0.05) (Figure 1b).
IL7R polymorphisms and severe liver disease
For rs6897932 polymorphism (Table  2A), patients with 
rs6897932 CC genotype had higher frequency of A3 in 
liver biopsy (p = 0.023) and had higher likelihood of hav-
ing A3 than patients with rs6897932 CT/TT [adjusted 
odds ratio (aOR) = 4.16; p = 0.026].
For rs987106 polymorphism (Table  2B), patients with 
rs987106 TT genotype had higher frequency of severe 
fibrosis (F ≥ 3, APRI ≥1.5, and FIB4 ≥3.25) than patients 
with rs987106 AA/AT genotype (p =  0.019, p =  0.033, 
and p  =  0.050; respectively). Furthermore, rs987106 
TT genotype was related to higher odds of having F ≥ 3 
(aOR = 3.09; p = 0.009).
For rs3194051 polymorphism (Table  2C), patients 
with rs3194051 AA genotype had higher frequency 
of F ≥  3 (p =  0.026), APRI ≥1.5 (p =  0.016), and FIB4 
≥3.25 (p = 0.022). Besides, patients with rs3194051 AA 
genotype had higher odds of having severe liver fibrosis 
(F ≥  3; APRI ≥1.5, and FIB4 ≥3.25) than patients with 
rs3194051 AG/GG genotype [aOR  =  2.73 (p  =  0.010); 
aOR  =  2.52 (p  =  0.029); and aOR  =  4.01 (p  =  0.027); 
respectively].
Three major haplotypes (comprised of rs6897932, 
rs987106, and rs3194051) were found (Table  3): CTA, 
CAG, and TAA. The CTA haplotype carriers had higher 
odds of having F ≥ 3 (aOR = 2.01; p = 0.007), APRI ≥1.5 
(aOR =  1.98; p =  0.028), and FIB4 ≥3.25 (aOR =  2.69; 
p  =  0.023). Conversely, CAG haplotype carriers had 
Table 1 Clinical and  epidemiological characteristics 
of HIV/HCV-coinfected patients
Values expressed as absolute numbers (%) and median (percentile 25; percentile 
75).
AIDS acquired immunodeficiency syndrome, APRI aspartate aminotransferase 
to platelet ratio, BMI body mass index, cART combination antiretroviral therapy, 
HCV hepatitis C virus, HCV-RNA HCV plasma viral load, HIV human immunode‑
ficiency, HIV-RNA HIV plasma viral load, HOMA homeostasis model assessment, 
IDU intravenous drug users, NNRTI no nucleoside analog reverse‑transcriptase 
inhibitors, NRTI nucleoside analog reverse‑transcriptase inhibitors, PI protease 
inhibitors.
Characteristics All patients
No. (%) 220 (100%)
Male, n (%) 162 (73.6%)
Age, years 39.8 (37.4; 44)
HIV acquired by IDU, n (%) 193 (87.7%)
Years since HCV infection 21.3 (17.1; 24.4)
Prior AIDS, n (%) 60 (27.3%)
cART, n (%) 183 (83.2%)
Time on cART, years 4.4 (2.5; 6.7)
Current cART protocols, n (%)
 PI‑based 50 (22.7%)
 NNRTI‑based 114 (51.8%)
 NRTI‑based 129 (58.6%)
Metabolic markers
 BMI, kg/m2 22.4 (20.8; 24.6)
 BMI ≥25 kg/m2 50 (22.9%)
 HOMA 2.10 (1.27; 3.73)
 HOMA ≥3 71 (33.5%)
HIV markers
 Nadir CD4+, T cells/μL 192 (84; 318)
 CD4+, T cells/μL 467 (324; 672)
 HIV‑RNA <50 copies/mL, n (%) 162 (73.6%)
HCV markers, n (%)
 HCV‑RNA ≥500.000 IU/ml 162 (74.7%)
 HCV genotype 216 (98.2%)
 HCV‑GT1 123 (55.9%)
 HCV‑GT2 5 (2.3%)
 HCV‑GT3 50 (22.7%)
 HCV‑GT4 38 (17.3%)
Metavir score, n (%)
 Significant fibrosis (F ≥ 2) 109 (49.5%)
 Advanced fibrosis (F ≥ 3) 49 (23.3%)
 Cirrhosis (F4) 23 (10.5%)
 Moderate activity grade (A ≥ 2) 114 (52.8%)
 Severe activity grade (A3) 24 (11.1%)
Fibrosis indexes
 APRI 0.75 (0.45; 1.30)
 APRI ≥1.5 36 (17.2%)
 FIB‑4 1.43 (1.03; 2.03)
 FIB‑4 ≥3.25 20 (9.6%)
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lower odds of having F  ≥  3 (aOR  =  0.42; p  =  0.004), 
APRI ≥1.5 (aOR  =  0.45; p  =  0.026), and FIB4 ≥3.25 
(aOR = 0.24; p = 0.007).
Discussion
To our knowledge, this study is the first description of 
the relation between IL7R polymorphisms and sever-
ity of liver disease in HIV/HCV-coinfected patients. The 
major findings of our study were: (1) IL7R rs6897932 CC 
was associated with higher odds of having severe activ-
ity necroinflammatory grade; (2) IL7R rs987106 TT 
and rs3194051 AA genotypes were related to increased 
odds of having severe fibrosis; and (3) IL7R CTA haplo-
type was associated with severe fibrosis while IL7R CAG 
haplotype had a protective nature. Moreover, these rela-
tionships were less evident when patients were stratified 
by HCV genotype (data not shown), perhaps due to a 
smaller sample size of the groups.
The rs6897932 C/T polymorphism is a missense variant 
located in the alternatively spliced exon 6 of IL7R gene, 
causing a substitution of threonine with isoleucine in the 
transmembrane domain of the IL7R gene. This polymor-
phism is implicated in splicing regulation, where the C 
allele leads to increased skipping of exon 6 by putatively 
disrupting an exonic splicing motif [36], increasing the 
production of sCD127 (soluble isoform) and decreas-
ing CD127 levels (membrane-bound isoform). In this 
setting, rs6897932 CC genotype has been associated 
to higher plasma levels of sCD127 in Caucasian HIV-
infected patients [14, 37], which binds to circulating IL-7 
and decreases the IL-7 bioavailability, limiting its effects 
[38]. Thus, rs6897932 C allele has been related to slower 
CD4+ T-cell recovery in European HIV infected patients 
on cART [39]. In our study, patients with rs6897932 CC 
genotype had higher odds of severe necroinflammatory 
activity grade. Given that the IL7R rs6897932 CC geno-
type is related to increased risk of autoimmune diseases 
[36, 40], it is possible to speculate that higher level of 
sCD127 may confer worse immunological control of 
HCV infection in liver, with a higher necroinflammatory 
activity in liver biopsy. However, further studies investi-
gating the underlying mechanisms are warranted.
In our study we also found that rs987106 TT and 
rs3194051 AA genotypes were related to higher odds 
of having severe liver fibrosis. The rs987106 polymor-
phism is an intronic variant between exons 6 and 7 of 
IL7R gene and rs3194051 is a missense polymorphism 


























Gene SNP Posion HWE p-value Alleles MAF
IL7RA rs987106 35875593 0.159 A/T 0.201
rs6897932 35874575 0.846 C/T 0.479





Figure 1 a Pairwise linkage disequilibrium (LD) patterns for three polymorphisms through IL7RA regions. Each diagonal represents a different SNP, 
with each square representing a pairwise comparison between two SNPs. b Allele and genotype frequencies, Hardy–Weinberg Equilibrium (HWE) 
and linkage disequilibrium (LD) for IL7RA polymorphisms (rs987106, rs6897932 and rs3194051) in HIV/HCV coinfected patients. HWE Hardy–Wein‑
berg equilibrium, MAF minor allele frequency, SNP single nucleotide polymorphism.
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Table 2 Relationship between IL7RA polymorphisms and severe liver disease in HIV/HCV-coinfected patients
Statistically significant differences are shown in italics.
HCV hepatitis C virus, HIV human immunodeficiency virus, CHC chronic hepatitis C, 95% CI 95% of confidence interval, aOR adjusted odds ratio, p value level of signifi‑
cance, A3 severe activity grade (Metavir), F ≥ 3 advanced liver fibrosis (Metavir), APRI aspartate aminotransferase to platelet ratio index.
a p values were calculated by Chi squared test.
b p values were calculated by multivariate logistic regression adjusted by the most important clinical and epidemiological characteristics (see “Statistical analysis” sec‑
tion).
Unadjusted Adjusted
CT/TT CC Pa aOR (95% CI) pb
(A) rs6897932
 F ≥ 3 20.5% (17/83) 23.4% (32/137) 0.619 1.14 (0.54;2.32) 0.735
 APRI ≥1.5 15% (12/80) 18.6% (24/129) 0.502 1.14 (0.48;2.68) 0.770
 FIB4 ≥3.25 10% (8/80) 9.3% (12/129) 0.868 0.80 (0.25;2.56) 0.705
 A3 4.9% (4/82) 14.9% (20/134) 0.023 4.16 (1.19;14.59) 0.026
Unadjusted Adjusted
AA/AT TT Pa aOR (95% CI) pb
(B) rs987106
 F ≥ 3 18.8% (32/170) 34.7% (17/49) 0.019 3.09 (1.32;7.22) 0.009
 APRI ≥1.5 14.3% (23/161) 27.7% (13/47) 0.033 1.84 (0.72;4.70) 0.201
 FIB4 ≥3.25 7.5% (12/161) 17% (8/47) 0.050 2.33 (0.67;8.05) 0.181
 A3 10.1% (17/168) 14.9% (7/47) 0.358 1.82 (0.63;5.23) 0.269
Unadjusted Adjusted
AG/GG AA Pa aOR (95% CI) pb
(C) rs3194051
 F ≥ 3 16.7% (20/120) 29.3% (29/99) 0.026 2.73 (1.22;5.87) 0.010
 APRI ≥1.5 11.5% (13/113) 24.2% (23/95) 0.016 2.52 (1.10;5.77) 0.029
 FIB4 ≥3.25 5.3% (6/113) 14.7% (14/95) 0.022 4.01 (1.17;13.71) 0.027
 A3 12.6% (15/119) 9.4% (9/96) 0.455 0.79 (0.30;2.10) 0.634
Table 3 Association of  IL7RA haplotypes (rs987106, rs6897932 and  rs13126816) with  severe liver disease in  HIV/HCV 
coinfected patients
P values were calculated by multivariate logistic regression adjusted by the most important clinical and epidemiological characteristics (see “Statistical analysis” sec‑
tion). Statistically significant differences are shown in italics.
95% CI 95% of confidence interval, aOR adjusted odds ratio, p value level of significance, A3 severe activity grade (Metavir), F ≥ 3 advanced liver fibrosis (Metavir), APRI 
aspartate aminotransferase to platelet ratio index, NA not available due to a low number of patients in one of the groups.
IL7RA haplotypes Adjusted
rs6897932 rs987106 rs3194051 Freq. Outcomes aOR (95% CI) p value
C T A 47.9% F ≥ 3 2.01 (1.19;3.40) 0.007
APRI ≥1.5 1.98 (1.06;3.71) 0.028
FIB4 ≥3.25 2.69 (1.10;6.60) 0.023
A3 NA –
C A G 31.5% F ≥ 3 0.42 (0.22;0.78) 0.004
APRI ≥1.5 0.45 (0.22;0.94) 0.026
FIB4 ≥3.25 0.24 (0.07;0.76) 0.007
A3 NA –
T A A 20.1% F ≥ 3 0.86 (0.44;1.67) 0.647
APRI ≥1.5 0.92 (0.42;2.04) 0.838
FIB4 ≥3.25 1.07 (0.35;3.26) 0.904
A3 NA –
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to be involved in post-transcriptional regulation and 
besides, rs3194051 is also predicted to be implicated in 
proximal transcriptional regulation of CD127, accord-
ing to an in silico analysis by using rSNPBase software 
[41]. In regards to rs987106, previous articles have 
described an association between rs987106 TT geno-
type and higher sCD127 levels [14] and rapid AIDS 
progression [13]. The rs3194051 polymorphism, a tag 
SNP of IL7R haplotype 4 in European populations, has 
been associated with highest CD127 on CD4+ T-cell, 
higher frequencies of recent thymic emigrants, and 
lower plasma sCD127 levels in patients with multiple 
sclerosis [42]. Thus, the rs3194051 A allele ancestral 
would be associated with lower CD127 on CD4+ T-cell, 
lower frequencies of recent thymic emigrants, and 
higher plasma sCD127 levels. Furthermore, rs3194051 
A allele has been associated with slower CD4+ recovery 
in HIV infected patients on cART [14] and lower odds 
of achieving sustained virological response (SVR) after 
pegIFNα/ribavirin in HIV/HCV coinfected patients 
[15].
Moreover, as noted in the preceding paragraphs, 
unfavorable alleles of these three IL7R polymorphisms 
(rs6897932 C, rs987106 T, and rs3194051 A) have been 
related to low CD4+ T-cells and rapid AIDS progression 
in Caucasian naïve HIV infected patients [13] and slower 
CD4+ recovery in patients on cART [14, 39]. Besides, 
uncontrolled HIV replication and low CD4 counts are 
both associated with accelerated liver fibrosis progres-
sion in HIV/HCV coinfected patients [23]. Thus, unfa-
vorable IL7R genotypes (rs6897932 CC, rs987106 TT, 
and rs3194051 AA) could lead to an increased risk of 
severe liver disease, by decreasing CD4+ cells count and 
enhancing AIDS progression in HIV/HCV coinfected 
patients [43].
In our study, IL7R haplotypes (comprised of rs6897932, 
rs987106, and rs3194051) were also investigated to ver-
ify whether they could improve the association of severe 
fibrosis compared to IL7R polymorphisms alone. We 
found that CTA haplotype was associated with higher 
odds of having severe liver fibrosis; while CAG haplotype 
(comprised of one allele associated with higher sCD127 
levels and two alleles related to lower sCD127 levels) was 
associated with lower odds of having severe liver fibrosis. 
However, OR values were similar to those obtained for 
individual SNPs. In this regard, we also recently reported 
that IL7R CTA haplotype (three alleles associated with 
higher sCD127 levels) was related to lower odds of 
achieving a SVR [15].
According to what we have discussed until now, IL7R 
polymorphisms are related to increased odds of hav-
ing severity of liver disease, possibly due to regulation 
of sCD127 levels. Previous reports have suggested that 
IL-7R polymorphisms may have an influence on T-cell 
development and homeostasis, and thereby might 
contribute to an altered immune regulation [42, 44]. 
Moreover, the CHC progression, which includes cir-
rhosis, end-stage liver disease, and hepatocellular 
carcinoma, is more rapid in HIV-infected patients, 
possibly because a damaged immune system may 
increase the risk for CHC progression among persons 
infected with HIV [45–47]. Therefore, one should not 
rule out the possible influence of IL7R polymorphisms 
in the development of end-stage of liver disease and 
hepatocellular carcinoma in HIV/HCV coinfected 
patients.
In our study, we compared the IL7R genotype fre-
quencies depending on the presence of each of the out-
come variables (independent events), which generated 
a high number of comparisons. There is a considerable 
controversy about adjusting the “p value” after multi-
ple tests on clinical-orientated studies [48, 49]. In our 
study there was a hypothesis supported by theory and 
previous reports in several infectious diseases [10, 11], 
including HIV infected subjects [13, 14] and HIV/HCV 
coinfected patients [15], and showing a key role of IL7R 
polymorphisms in the evolution of patients. Therefore, 
we were not literally doing a random search of a mean-
ingful result, and our results should not be affected by 
the fact of carrying out a high number of statistical tests. 
Moreover, since p value is depending on the sample size, 
only big effects would be detected in small populations 
and it may be possible that we did not find any signifi-
cant adjusted p value in some comparisons due to our 
size-limited population. We should take into account the 
fact that the effect size of our study is low since complex 
human diseases are under the control of many genes, 
each one of them contributing with modest individual 
effects [50].
There are other aspects to be taken into account for 
the correct interpretation of the results. Firstly, this is 
a cross-sectional study with data collected retrospec-
tively. Secondly, the study contains a limited number of 
patients, which could limit achieving statistically signifi-
cant p values in some groups and it may lead to poten-
tially large percentage fluctuations in the proportion. 
Thirdly, all selected patients met a set of criteria for start-
ing HCV treatment and this may have introduced a selec-
tion bias. Fourthly, this study was performed on patients 
with European ancestry, and it would be interesting to 
perform these analyses on different ethnic groups. Fifthly, 
our study only included HIV/HCV-coinfected patients 
and it would be interesting to know the role of studied 
IL7R polymorphisms in HCV monoinfected patients, but 
we did not have access to a cohort of HCV monoinfected 
patients.
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Conclusions
The presence of IL7R polymorphisms seems to be related 
to severe liver disease in HIV/HCV coinfected patients, 
because patients with unfavorable IL7R genotypes 
(rs6897932 CC, rs987106 TT, and rs3194051AA) had a 
worse prognosis of CHC.
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